NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2011
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Clinical Trials (5)
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Started Sep 2014
11 enrolled
HIV Infections
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
Started Aug 2014
46 enrolled
HIV-1
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Started Apr 2014
150 enrolled
HIV
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
Started Mar 2012
398 enrolled
HIV Infections
A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance
Started Feb 2011
60 enrolled
HIVHIV Infections
Loss of Exclusivity
LOE Date
Mar 12, 2029
36 months away
Patent Expiry
Mar 12, 2029
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8460704 | Mar 12, 2029 | U-1409 |